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INTRODUCTORY PARAGRAPH  
Primary aldosteronism is the most common and curable form of secondary arterial 
hypertension. We performed whole exome sequencing in patients with early-onset primary 
aldosteronism and identifed a de novo heterozygous c.71G>A/p.Gly24Asp mutation in the 
CLCN2 gene, coding for the voltage-gated ClC-2 chloride channel 1, in a patient diagnosed at 
age 9 ys. Patch-clamp analysis of glomerulosa cells of mouse adrenal gland slices revealed 
hyperpolarization-activated Cl- currents that were abolished in Clcn2-/- mice. The p.Gly24Asp 
mutation, located in a well conserved ‘inactivation domain’ 2,3, abolished the voltage- and 
time-dependent gating of ClC-2 and strongly increased Cl- conductance at resting potentials. 
Expression of ClC-224Asp in adrenocortical cells increased expression of aldosterone synthase 
and aldosterone production.  
Our data indicate that CLCN2 mutations cause primary aldosteronism. They highlight for the 
first time the important role of chloride in aldosterone biosynthesis and identify ClC-2 as the 
foremost chloride conductor of resting glomerulosa cells. 
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MAIN TEXT  1 
Arterial hypertension is a major cardiovascular risk factor 4. Primary aldosteronism is 2 
the most common and curable form of secondary arterial hypertension, with an estimated 3 
prevalence of ~10% in referred patients and 4% in primary care5, and up to 20% of patients 4 
with resistant hypertension 6. Primary aldosteronism results from autonomous aldosterone 5 
production in the adrenal cortex 7, caused in most cases by a unilateral aldosterone-producing 6 
adenoma or bilateral adrenal hyperplasia (BAH). It is diagnosed on the basis of hypertension 7 
associated with increased aldosterone to renin ratio and often hypokalemia 8. Compared to 8 
essential hypertension, increased aldosterone levels in primary aldosteronism are associated 9 
with increased cardiovascular risk in particular coronary artery disease, heart failure, renal 10 
damage and stroke 9,10.  11 
Gain-of-function mutations in different genes, coding for cation channels (KCNJ5 11, 12 
CACNA1D 12,13, CACNA1H 14,15) and ATPases (ATP1A1 and ATP2B3, 12,16), regulating 13 
intracellular ion homeostasis and plasma membrane potential, have been described in 14 
aldosterone producing adenoma and familial forms of primary aldosteronism, but the 15 
pathophysiology of many cases is still unknown.   16 
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We performed whole exome sequencing on germline DNA from 12 patients with young onset 17 
hypertension and hyperaldosteronism diagnosed before age 25 ys. Two index cases were 18 
investigated together with their parents and unaffected sibling to search for de novo variants. 19 
A de novo germline CLCN2 variant c.71G>A (NM_004366; p.Gly24Asp) was identified in 20 
subject K1011-1, but not in her asymptomatic parents (K1011-3 and K1011-4) and sibling 21 
(K1011-2, Fig. 1a and 1b, Table 1). The variant was absent from more than 120.000 alleles in 22 
the Exome Aggregation Consortium (ExAC) and in our in-house database. We did not find 23 
additional CLCN2 variants among the other 11 investigated individuals. CLCN2 encodes the 24 
chloride channel ClC-2. The variant CLCN2 p.Gly24Asp localizes to its N-terminal 25 
cytoplasmic domain (Fig. 1c, d).  Gly24 is highly conserved in ClC-2 orthologs of species as 26 
distant as zebrafish and Xenopus (Fig. 1c). 27 
The patient carrying the CLCN2 p.Gly24Asp variant is a 9 year old girl, who presented 28 
with severe headache and vomiting lasting for 1 year (Table 1). The child was 29 
developmentally normal, first born to a non-consanguineous couple. There was history of 30 
mild hypertension in maternal grandmother and granduncle. Blood pressure (BP) was 172/100 31 
mm Hg, heart rate was 120/minute. The rest of the examination was normal. Her work-up 32 
revealed persistent hypokalemia (serum K+ ranging from 1.8 to 2.4 meq/L), elevated serum 33 
aldosterone (868.1 pg/ml, reference range 12-340 pg/ml) and suppressed plasma renin activity 34 
(0.11 ng/ml/hr, reference range 1.9 to 6.0 ng/ml/hr in upright posture), suggestive of primary 35 
aldosteronism. Abdominal CT scan showed no adrenal abnormalities. Other parameters 36 
including 24 hours urinary vanillylmandelic acid and serum cortisol were normal. 37 
Hypertension was initially managed with amlodipin, enalapril and atenolol. Once the 38 
diagnosis of primary aldosteronism was made, spironolactone was added, enalapril was 39 
stopped and doses of amlodipin and atenolol were reduced. Serum K+ normalized. A positive 40 
glucocorticoid suppression test (aldosterone 949.3 pg/ml at baseline and 56.9 pg/ml after 41 
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administration of oral dexamethasone 0.5 mg every 6 hours for 48 hours) suggested the 42 
possibility of glucocorticoid remediable aldosteronism (GRA), a rare familial form of 43 
hyperaldosteronism 17. However, genetic analysis for a chimeric CYP11B1/CYP11B2 gene 44 
was negative. The child’s hypertension has been well controlled over the last 18 months with 45 
prednisolone 5mg/m2/day, spironolactone and amlodipin. On treatment, her serum aldosterone 46 
and plasma renin are 421 pg/ml (reference range 25 to 392) and 8.22 µU/mL (4.4 to 46.1). 47 
After exclusion of GRA by genetic testing, prednisolone treatment was stopped. 48 
Cl- conductances can regulate the excitability of neuronal, muscle, and endocrine cells 49 
18-21 . In zona glomerulosa cells, ACTH-activated Cl- currents have been described 22, but their 50 
outward rectification sets them apart from hyperpolarization-activated ClC-2 currents. ClC-2 51 
is expressed in almost all tissues 1 and may have roles in ion homeostasis and transepithelial 52 
transport 23. Clcn2−/− mice display early postnatal retinal and testicular degeneration 24 as well 53 
as leukodystrophy 25,26; in humans, CLCN2 loss-of-function mutations result in 54 
leukodystrophy27 that may be associated with azoospermia28. These phenotypes have been 55 
ascribed to a role of ClC-2 in extracellular ion homeostasis 24,25.  56 
Data retrieved from a transcriptome analysis including eleven human adrenals 29 57 
showed high expression of CLCN2 in human adrenal cortex (Supplementary Table 1). In 58 
mice, Western blots revealed similar expression of ClC-2 in whole adrenal gland as in brain 59 
(Fig. 2a), which expresses substantial, physiologically important amounts of ClC-2 25. Patch-60 
clamp analysis of glomerulosa cells in situ revealed typical hyperpolarization-activated 61 
currents in WT, but not in Clcn2-/- mice (Fig. 2 b,c). Their magnitude was similar to those 62 
observed in Bergmann glia which prominently express ClC-2 26. The almost complete 63 
absence of Cl- currents in Clcn2-/- cells demonstrates that under resting conditions ClC-2 64 
mediates the bulk of glomerulosa cell Cl- currents.   65 
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The CLCN2 p.Gly24Asp mutation is located in a highly conserved ‘inactivation 66 
domain’ 2,3 of the channel. Deletions and point mutations in this region and an intracellular 67 
loop 2 (highlighted in Fig. 1c, d) lead to  ‘open’ ClC-2 channels that have lost their sensitivity 68 
to voltage, cell swelling, or external pH 2,3. Likewise, insertion of the p.Gly24Asp mutation 69 
drastically changed voltage-dependent gating of ClC-2 (Fig. 2d,e,h) and dramatically 70 
increased current amplitudes when expressed in Xenopus oocytes (Fig. 2d-g). When measured 71 
at -80 mV, the approximate resting potential of glomerulosa cells 30, current amplitudes from 72 
the mutant channel were much larger compared to WT (Fig. 2d-f). Linear, ohmic currents like 73 
those of the mutant channel might be due to unspecific electrical leaks; however, currents of 74 
both WT and mutant ClC-2 were markedly reduced when extracellular chloride was replaced 75 
by iodide (Fig. 2d-f),  agreeing with the Cl->I- selectivity of CLC channels in general 23 and 76 
ClC-2 in particular 1. The activation of ClC-2 by acid extracellular pH can be almost 77 
abolished by mutations in the ‘inactivation domain’2. Likewise, the ClC-224Asp mutant had 78 
largely reduced pH sensitivity (Fig. 2i-j, Supplementary Fig.1). In conclusion, the 79 
p.Gly24Asp mutation results in a strong gain of function, explaining the dominant disease 80 
phenotype of the mutation that is present at the heterozygote state. It also suggests a 81 
pathophysiological mechanism in which a strong increase in Cl- currents may depolarize 82 
glomerulosa cells, thereby opening voltage-gated Ca2+ channels and activating transcriptional 83 
programs via an increase of cytosolic Ca2+.  84 
Expression of the mutant ClC-224Asp channel in adrenocortical H295R-S2 cells, and 85 
conversely, knock-down of ClC-2 by shRNA significantly affected aldosterone production 86 
and expression of steroidogenic enzymes. Despite similar expression of ClC-2 in H295R-S2 87 
cells stably transfected with ClC-224Asp or ClC-2WT (Fig. 3a and 3b), aldosterone synthase 88 
expression (Fig. 3a and 3c) and aldosterone production (Fig. 3d, e) were significantly 89 
increased in ClC-224Asp expressing cells. Stimulation with angiotensin II (AngII 10nM) or K+ 90 
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(12mM) increased aldosterone production in cells expressing WT ClC-2 (Fig. 3e). A further 91 
increase was observed in cells expressing ClC-224Asp after AngII stimulation, but not after K+ 92 
stimulation (Fig. 3e). Nevertheless, also after stimulation, aldosterone production in cells 93 
expressing ClC-224Asp was significantly higher compared to cells expressing ClC-2WT (Fig. 94 
3e). Infection of H295R-S2 cells with ClC-2 shRNA reduced CLCN2 expression by ~50% 95 
(Supplementary Fig. 2a) compared with a scrambled shRNA, and significantly reduced 96 
aldosterone production, both at baseline and after stimulation (Supplementary Fig. 2b), 97 
suggesting that even WT ClC-2 currents, although much smaller than currents from the 98 
Gly24Asp mutant, significantly increase the excitability of H295R-S2 adrenocortical cells. 99 
These changes were paralleled in both models by concomitant modifications of the expression 100 
of steroidogenic genes. A significant increase of mRNA expression of CYP11B2 (encoding 101 
aldosterone synthase, Fig. 3f), StAR (encoding the Steroidogenic acute regulatory protein, Fig. 102 
3g) and CYP21A2 (encoding Steroid 21-hydroxylase, Fig. 3h) was observed in ClC-224Asp 103 
compared with ClC-2WT overexpressing cells in basal conditions. AngII increased expression 104 
of StAR and CYP11B2, while K+ stimulation increased mRNA expression of CYP11B2. 105 
Conversely, knock-down of ClC-2 led to a significant decrease in CYP11B2 expression in all 106 
conditions (Supplementary Fig. 2c). These data further support the notion that a gain-of-107 
function CLCN2 mutation may depolarize the cell, activate the steroidogenic pathway, and 108 
increase aldosterone production. While knock-down of ClC-2 influences aldosterone 109 
production in H295R-S2 cells which have a resting potential of about – 65 mV (Fig. 4a, b), 110 
this may not be the case in native glomerulosa cells. Because their Vm is close to the K+ 111 
equilibrium potential 30, they are unlikely to markedly hyperpolarize upon loss of ClC-2. No 112 
changes of blood pressure have been reported for mice or patients lacking ClC-2 24,25,27, but 113 
this issue has not been investigated in detail. 114 
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We next explored the effect of the ClC-2 Gly24Asp mutation on the membrane 115 
potential and on calcium influx through voltage-gated calcium channels. These studies were 116 
performed with the perforated patch clamp technique which does not disturb the intracellular 117 
chloride concentration and is required to see the full effect of ‘inactivation domain’2,3 118 
mutations31,32. In the stably transfected H295R-S2 cells used to investigate steroidogenesis 119 
(Fig. 3), there was a trend of Vm to be depolarized in ClC-224Asp transfected compared to ClC-120 
2WT transfected cells (mean values of roughly -52 and -67 mV, respectively) (Fig. 4a). 121 
However, because these cell lines are not clonal, the variability was large and the difference 122 
was not statistically significant.  123 
We therefore resorted to transient transfection of H295R-S2 cells which allowed us to 124 
select ClC-2 expressing cells by fluorescence of co-transfected GFP (Fig. 4b-g). Although 125 
these cells express ClC-2 less efficiently than Xenopus oocytes (compare Fig. 4f and 2d) and 126 
HEK cells 31,32, ClC-224Asp expressing cells displayed robust chloride currents that lacked 127 
strong voltage-dependence (Fig. 4c-g). The observed increase in currents may reflect both an 128 
increase in currents per channel and in the number of channels; both must be considered when 129 
analyzing pathogenic effects of ion channel mutants. This increase in curents correlated with a 130 
strong depolarization from Vm= - 65  ± 4 (ClC-2WT)  to -46 ± 4 mV in ClC-224Asp transfected 131 
cells (Fig. 4b), indicating that chloride concentration in H295R-S2 cells is higher than 132 
predicted by the electrochemical equilibrium. This depolarization may open voltage-133 
dependent calcium channels. Indeed, nifedipine (an L-type calcium channel blocker) and/or 134 
mibefradil (a T-type calcium channel blocker) strongly reduced aldosterone production in 135 
cells expressing the ClC-224Asp mutant (Fig. 4i). The involvement of L-type calcium channels 136 
appeared to be larger in ClC-224Asp expressing cells (Fig. 4h), possibly because of their 137 
depolarized plasma membrane potential which is required to open these channels 33. However, 138 
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we cannot exclude that nifedipine acted partially through T-type calcium channels, which are 139 
also blocked by this compound at depolarized voltages34.  140 
To investigate whether the CLCN2 p.Gly24Asp mutation could be involved in other 141 
forms of primary aldosteronism, we sequenced exon 2 of CLCN2 in 100 patients with BAH. 142 
While CLCN2 p.Gly24Asp was not identified among these subjects, we identified two rare 143 
CLCN2 variants, c.197G>A (p.Arg66Gln, rs755883734) and c.143C>G (p.Pro48Arg, 144 
rs115661422) in two subjects (Supplementary Fig. 3). Minor allele frequencies of these 145 
variants are very low in the ExAC database (CLCN2 p.Arg66Gln 0.00003; CLCN2 146 
p.Pro48Arg 0.0017). Both variants failed to significantly change ClC-2 currents in 147 
heterologous expression (Supplementary Fig. 4), in spite of a previously described35 moderate 148 
reduction of ClC-2Pro48Arg current amplitudes. Nonetheless, it is noteworthy that the two 149 
patients were diagnosed with hypertension at young age, 29 and 19 ys respectively (Table 1) 150 
and in both cases during pregnancy. Finally, sequencing the CLCN2 exons encoding the N-151 
terminal domain (exon 1 and 2) and the loop between helices J and K (exon 10), 152 
corresponding to the ClC-2 ‘inactivation domains’2,3, in 20 additional patients with 153 
hypertension before age 20 did not identify additional mutations. Among these patients, nine 154 
had a history of hypertension before the age of 15 years (one before age 10 ys), indicating that 155 
CLCN2 mutations might underlie very young onset forms of primary aldosteronism. 156 
In conclusion, we show that a gain-of-function mutation in the ClC-2 chloride channel 157 
underlies a genetic form of secondary arterial hypertension and identify ClC-2 as the foremost 158 
chloride conductor of resting glomerulosa cells. We suggest that increased Cl- currents 159 
induced by the ClC-2 p.Gly24Asp mutation could depolarize the zona glomerulosa cell 160 
membrane, thereby opening voltage-gated calcium channels which trigger autonomous 161 
aldosterone production by increasing intracellular Ca2+ concentrations (Fig. 5b, red arrows). 162 
We hypothesize that the increased Cl- currents may overcome the hyperpolarizing currents of 163 
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K+ channels that normally determine the glomerulosa cell resting potential. The inhibition of 164 
these potassium channels e.g. upon AngII stimulation, or the depolarizing currents mediated 165 
by these channels upon increases in extracellular K+, are the main mechanisms triggering 166 
aldosterone production under physiological conditions (Fig. 5a, dashed black arrows). 167 
Not only mutations in the amino-terminal ClC-2 ‘inactivation domain’ 2,3, like the 168 
Gly24Asp mutation found here, but also in the cytoplasmic linker between transmembrane 169 
helices J and K may cause primary aldosteronism (Fig. 1d). Several point mutations in that 170 
linker result in constitutively open ClC-2 channels 2.  We propose both regions as potential 171 
hotspots for mutations causing primary aldosteronism. The discovery that a chloride channel 172 
is involved in primary aldosteronism opens new and unexpected perspectives for the 173 
pathogenesis and treatment of arterial hypertension.   174 
  175 
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FIGURE LEGENDS 292 
Figure 1. A CLCN2 variant identified in a patient with early onset primary 293 
aldosteronism. (a) Pedigree of kindred K1011. The subject with PA is shown with a black 294 
symbol and non-affected subjects are shown with white symbols. (b) Sanger sequencing 295 
chromatograms showing the CLCN2 wild-type sequence of the unaffected parents (K1011-3 296 
and K1011-4) and brother (K1011-2) and the CLCN2 variant c.71G>A (p.Gly24Asp) 297 
identified in the patient with early onset primary aldosteronism (K1011-1). (c) Alignment and 298 
conservation of residues encoded by CLCN2 orthologs. The red box indicates the amino-299 
terminal 'inactivation domain' of ClC-2. Several deletions and mutations in this region of rat 300 
ClC-2 led to constitutive open ClC-2 channels (uninterrupted line) or partially opened 301 
channels (dashed line) 3. Residues that are conserved among more than 3 sequences are 302 
highlighted in yellow. (d) Position of the disease-causing Gly24Asp mutation in the ClC-2 303 
protein (schematic transmembrane topology drawing modified from 36). ‘Inactivation 304 
domains’ previously identified by structure-function analysis in the amino-terminus 3 and an 305 
intracellular loop 2 of ClC-2 are shown in red. Several point mutations and deletions in these 306 
domains open the ClC-2 channel 2,3 similar to the Gly24Asp substitution described here. 307 
CBS1 and CBS2, cystathionine-β-synthase domains which can affect gating of CLC channels 308 
23. 309 
Figure 2 ClC-2 expression in mouse adrenals and electrophysiological analyses of WT 310 
and mutant channels.  (a) ClC-2 immunoblot of brain and adrenals from Clcn2 +/+ and Clcn2 311 
-/- mice.  All lanes are from the same blot, which has been cut as indicated. Similar amounts of 312 
protein were loaded with actin serving as loading control. This blot is representative for three 313 
independent experiments. (b) Representative whole-cell chloride current traces of mouse zona 314 
glomerulosa cells from Clcn2+/+ (top) and Clcn2-/- (bottom) adrenal slices using voltage steps 315 
as indicated above. (c) Mean ± SEM currents measured after 1.5 s from experiments in (b) 316 
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plotted as a function of clamp voltage.  (d, e)  Representative chloride current traces measured 317 
by two-electrode voltage-clamp from Xenopus oocytes injected with either human ClC-2WT 318 
(d) or ClC-224Asp (e) cRNA, using the protocol shown in (d).  For some measurements (below) 319 
extracellular chloride was replaced with iodide. (f) Mean ± SEM currents measured in (d,e) 320 
plotted as a function of voltage. Number of cells indicated in parenthesis. (g, h)  Summary of 321 
Cl- currents at -80 mV (I-80mV) (g) and current ratios (I-120mV / I+60mV) as measure of 322 
rectification (h) (always measured at 2s)  for panels (d-f).  ****p < 0.0001, Mann-Whitney 323 
two-tailed test. (i, j) Effect of external pH on currents mediated by ClC-2WT (i) or ClC-224Asp 324 
(j) in Xenopus oocytes. Currents were normalized to mean currents from respective construct 325 
measured after 2s at -120 mV and pH 7.4. Number of oocytes indicated in parenthesis, error 326 
bars indicate SEM. 327 
Figure 3. Effect of ClC-2WT and mutant ClC-224Asp channels on aldosterone production 328 
and expression of genes and proteins involved in aldosterone biosynthesis. (a) Western 329 
blots for ClC-2 and aldosterone synthase of H295R-S2 cells stably transfected with ClC-2WT 330 
or mutant ClC-224Asp. These blots are representative of three independent experiments, with 331 
actin serving as loading control. (b) Quantification of ClC-2 protein expression in ClC-2WT 332 
and ClC-224Asp H295R-S2 cells (T test p=0.10, F=3.19). (c) Quantification of aldosterone 333 
synthase expression in ClC-2WT or ClC-224Asp H295R-S2 cells (T test p=0.0025, F=136). (d) 334 
Basal aldosterone production by H295R-S2 cells transfected with ClC-2WT or mutant ClC-335 
224Asp (T test, p=0.0008, F=142).  (e) Basal and stimulated aldosterone production by H295R-336 
S2 cells transfected with ClC-2WT (open bars) or mutant ClC-224Asp (filled bars) (1way 337 
ANOVA p<0.0001, F=23.46).  (f-h) Basal and stimulated mRNA expression of (f) CYP11B2 338 
(1way ANOVA p<0.001, F=18.39), (g) STAR (Kruskal-Wallys p=0.0033), and (h) CYP21A2 339 
(1way ANOVA p<0.0001, F23.27) in H295R-S2 cells transfected with ClC-2WT (open bars) or 340 
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mutant ClC-224Asp (filled bars). Quantification of protein expression (using actin as loading 341 
control) and aldosterone production are represented as percentage of ClC-2WT in basal 342 
conditions and results of mRNA expression are represented as fold induction of ClC-2WT in 343 
basal conditions. Values of all experiments are represented as mean ± SEM of three 344 
independent experiments performed in experimental triplicates (n=9) for each condition. * 345 
p<0.05; ** p<0.01; *** p<0.001; i) p<0.05 stimulated vs basal condition, ii) p<0.01 346 
stimulated vs basal condition; iii) p<0.001 stimulated vs basal condition. 347 
Figure 4  Functional impact of the ClC-224Asp mutation. (a-g) Effect on membrane 348 
potential Vm and plasma membrane anion currents in H295R-S2 cells. (a) Resting membrane 349 
potential of ClC-2WT and ClC-224Asp stably transfected H295R-S2 cells which were used to 350 
determine aldosterone secretion. Note strong mean depolarization (ClC-2WT, -67 ± 2 mV 351 
(n=8); ClC-224Asp,  -52 ±  6 mV (n=12)), which, however, was not significant (Two-tailed 352 
Mann-Whitney p = 0.14) owing to large variability of Vm of ClC-224Asp transfected cells that 353 
were not cloned. (b) Similarly determined values of Vm for non-transfected, and transiently 354 
transfected H295R-S2 cells (non-transfected, -65 ±4 mV (n=8); ClC-2WT, -69 ± 7 mV (n=4); 355 
ClC-224Asp, -46 ± 4 mV (n=6); **, Two-tailed Mann-Whitney p = 0.0095))  (c,d) 356 
Corresponding plasma membrane currents measured after 1.5 s under conditions eliminating 357 
cation inward currents as function of voltage (c) or as plot of individual values at 358 
physiological Vm of glomerulosa cells (d) *, Two-tailed Mann-Whitney p = 0.019. (e-g) 359 
corresponding averaged current traces with 20 mV voltage steps between 0 and -120 mV. (h-i) 360 
Effect of calcium channel blockers on aldosterone production in H295R-S2 cells expressing 361 
(h) ClC-2WT (Kruskall Wallis p=0.0005) and (i) ClC-224Asp (Kruskal Wallis, p=0.0032). Values 362 
represent mean ± SEM of  two independent experiments performed in experimental triplicates 363 
(n=6) for each condition. * p<0.05; ** p<0.01.  364 
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 365 
Figure 5. Proposed model for autonomous aldosterone secretion in adrenal zona 366 
glomerulosa cells with the ClC-224Asp mutation. (a) In unstimulated conditions, the ZG cell 367 
membrane potential closely follows the potassium resting potential at approximately -80 mV. 368 
Increasing extracellular K+ concentration, or inhibition of K+ channels by AngII through its 369 
receptor (AT1R), leads to cell membrane depolarization, opening of voltage-gated Ca2+ 370 
channels, and increased intracellular calcium concentrations, the major trigger for aldosterone 371 
biosynthesis. Binding of AngII to AT1R also leads to Gαq-mediated signaling and IP3-372 
mediated release of Ca2+ from the endoplasmic reticulum. (b) The ClC-2 p.Gly24Asn 373 
mutation abolishes the voltage-dependent gating of ClC-2. The resulting pronounced increase 374 
of Cl- currents at resting potentials is proposed to result in cell depolarization, opening of 375 
voltage gated Ca2+ channel, stimulation of Ca2+ signaling, and finally increased expression of 376 
steroidogenic genes and aldosterone production.   377 
  378 
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Table 1. Clinical and biological characteristics of patients carriers of CLCN2 variants.  379 
 K1011-1 K963-1 K1044-1 
Sex F F F 
Age at HTN dg (ys) 9 19 29 
Age at primary aldosteronism dg (ys) 9 27 48 
SBP at primary aldosteronism dg (mmHg) 172 139 173 
DBP at primary aldosteronism dg (mmHg) 100 90 114 
Lowest plasma K+ (mmol/L) 1.8 2.9 2.5 
Urinary aldosterone (nmol/24h) ND 60 ND 
Plasma aldosterone (pmol/L)a 2406 927 1061 
Plasma renin (mU/L)a 0.9 1.9 <1 
ARR (pmol/mU)b 481.2 185.4 212.2 
Adrenal abnormalities on imaging No No No 
Lateralization at AVS ND No No 
dg, diagnosis; m, months; y, years ; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic 380 
blood pressure; K, potassium; ARR, aldosterone to renin ratio; Hormonal data are at diagnosis of 381 
primary aldosteronism. ND, not determined. For comparison within this table, plasma aldosterone 382 
levels for patient K1011-1 have been converted to pmol/L and plasma renin activity to plasma renin 383 
concentration. bfor ARR calculation, renin values <5 have been transformed to 5. Conversion factor 384 
used for plasma aldosterone: 1 ng/l = 2.77 pmol/L; conversion factor used for plasma renin: 1 ng/ml/h 385 
= 8.2 mU/L. 386 
  387 
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Online Methods 388 
Patients 389 
Patients with primary aldosteronism were recruited within the COMETE (COrtico- et 390 
MEdullo-surrénale, les Tumeurs Endocrines) network (COMETE-HEGP protocol, 391 
authorization CPP 2012-A00508-35) or in the context of genetic screening for familial 392 
hyperaldosteronism at the Genetics department of the HEGP. Methods for screening and 393 
subtype identification of primary aldosteronism were performed according to the Endocrine 394 
Society guidelines8. In patients diagnosed with primary aldosteronism, a thin slice CT scan or 395 
MRI of the adrenal and/or an adrenal venous sampling (AVS) were performed to differentiate 396 
between unilateral and bilateral aldosterone hypersecretion. All patients gave written 397 
informed consent for genetic and clinical investigation. Procedures were in accordance with 398 
institutional guidelines.  399 
 400 
DNA isolation  401 
DNA from peripheral blood leukocytes was extracted using QIAamp DNA midi kit (Qiagen, 402 
Courtaboeuf Cedex, France) or salt-extraction.  403 
 404 
Whole exome sequencing and variant detection 405 
Exomes were enriched in solution and indexed with SureSelect XT Human All Exon 50 Mb 406 
kits (Agilent). Sequencing was performed as 100 bp paired-end runs on HiSeq2000 systems 407 
(Illumina). Pools of 12 indexed libraries were sequenced on four lanes. Image analysis and 408 
base calling was performed using Illumina Real Time Analysis. CASAVA 1·8 was used for 409 
demultiplexing. BWA (v 0.5.9) with standard parameters was used for read alignment against 410 
the human genome assembly hg19 (GRCh37). We performed single-nucleotide variant and 411 
small insertion and deletion (indel) calling specifically for the regions targeted by the exome 412 
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enrichment kit, using SAMtools (v 0.1.18). Subsequently the variant quality was determined 413 
using the SAMtools varFilter script. We used default parameters, with the exception of the 414 
maximum read depth (-D) and the minimum P-value for base quality bias (-2), which we set 415 
to 9999 and 1e-400, respectively. Additionally, we applied a custom script to mark all 416 
variants with adjacent bases of low median base quality. All variants were then annotated 417 
using custom Perl scripts. Software is available on request (https://ihg4.helmholtz-418 
muenchen.de/cgi-bin/mysql/snv-vcf/login.pl). Annotation included information about known 419 
transcripts (UCSC Known Genes and RefSeq genes), known variants (dbSNP v 135), type of 420 
mutation, and - if applicable – amino acid change in the corresponding protein. The annotated 421 
variants were then inserted into our in-house database. To reduce false positives we filtered 422 
out variants that were already present in our database, had variant quality less than 40, or 423 
failed one of the filters from the filter scripts. We then manually investigated the raw read 424 
data of the remaining variants using the Integrative Genomics Viewer (IGV). 425 
 426 
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Sanger sequencing  427 
CLCN2 DNA was amplified using the intron-spanning primers described in supplementary 428 
table S2. PCR were performed on 100 ng of DNA in a final volume of 25 µl containing 0.75 429 
mM MgCl2, 400 nM of each primer, 200 µM deoxynucleotide triphosphate, and 1.25 U Taq 430 
DNA Polymerase (Sigma).  Cycling conditions for CLCN2 were as previously described 37 431 
with an annealing temperature of 60oC. Direct sequencing of PCR products was performed 432 
using the ABI Prism Big Dye Terminator® v3.1 Cycle Sequencing Kit (Applied Biosystems, 433 
Foster City, CA) on an ABI Prism 3700 DNA Analyzer (Applied Biosystems). 434 
 435 
Site directed mutagenesis 436 
The ClC-224Asp construct was generated by site-directed mutagenesis using the QuikChange II 437 
XL site-directed mutagenesis kit (Agilent). The mutation was introduced into the human ClC-438 
2 cDNA fragment inserted into the pFROG expression vector 38 and their presence confirmed 439 
by Sanger sequencing. 440 
 441 
Western blot 442 
The membrane fractions of tissue homogenate from brain and adrenal gland of adult Clcn2 +/+ 443 
and Clcn2 -/- mice were isolated and lysed in 50mM Tris pH 6.8, 140mM NaCl, 0.5mM 444 
EDTA and 2% SDS with protease inhibitors (4 mM Pefabloc and Complete® EDTA-free 445 
protease inhibitor cocktail, Roche). Equal amounts of protein were separated by SDS–PAGE 446 
(10 % polyacrylamide) and blotted onto nitrocellulose. Rabbit polyclonal antibodies against a 447 
modified carboxy-terminal ClC-2 peptide have been described previously 26. Blots were 448 
reprobed with mouse anti-β-actin (Clone AC-74, Sigma A2228, 1:1000) as a loading control. 449 
H295R-S2 cells were lysed using RIPA buffer (Bio Basic Canada Inc.) with protease and 450 
phosphatase inhibitors mini tablets, EDTA free (Thermo Scientific). Proteins were solubilized 451 
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for 30 min at 4°C, under end-over-end rotation, and then centrifuged at 13000 rpm for 15 min 452 
at 4°C. Equal amounts of proteins were submitted to 10% SDS-PAGE and transferred onto 453 
nitrocellulose membrane. Membranes were blotted with rabbit anti-ClC-2 antibody (1:500), 454 
mouse anti-aldosterone synthase antibody (1:500, clone CYP11B2-41-13, kindly provided by 455 
Dr C Gomez Sanchez39) and mouse anti-β-actin (A2228, 1:10000, Sigma). 456 
 457 
 458 
Electrophysiological recordings 459 
Patch clamp analysis were performed in adrenal sections from wild type and Clcn2-/- mice 24, 460 
similarly to previously described 40. Bicarbonate based buffers were used which were 461 
continuously bubbled with 95% O2 and 5% CO2.  Briefly, adrenal glands were removed and 462 
placed into cold low-Ca2+ solution composed of (in mM): 140 NaCl, 2 KCl, 26 NaHCO3, 10 463 
glucose, 5 MgCl2, 0.1 CaCl2, pH 7.4. The adrenals, after removal of surrounding fat tissue, 464 
were embedded in 3% low-melting agarose, sectioned at 70 µm (Leica VT1200S), and 465 
incubated at room temperature in solution containing: 140 NaCl, 2 KCl, 26 NaHCO3, 10 466 
glucose, 2 MgCl2, 2 CaCl2, and adjusted to pH 7.4.  After at least 1 hour, slices were then 467 
transferred to a recording chamber and imaged with a 60x objective and DIC optics (Olympus 468 
BX51WI). Cells of the zona glomerulosa were identified by their rosette organization.  469 
Electrical signals were acquired at room temperature using a microelectrode amplifier 470 
(Multiclamp 700B) and software (Clampex 10.3, Molecular Devices, USA).  As expected, 471 
cells when patched with a K+-based solution displayed spontaneous spiking which could be 472 
stimulated with angiotensin II.  For measuring chloride currents, patch pipettes were filled 473 
with solution containing: 117.5 CsMeSO3, 17.5 CsCl, 4 NaCl, 10 Hepes, 1 EGTA, 1 MgCl2, 474 
adjusted to pH 7.3 while the bath solution contained: 117 NMDG-Cl, 23 NMDG-HCO3, 5 475 
CsCl, 1.3 MgCl2, 9 glucose, 2 CaCl2, adjusted to pH 7.3. Voltage steps from +40 to −120 mV 476 
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from a holding potential of −10 mV were used, with a final 1 s step at +40 mV. Signals were 477 
digitized at 10 kHz, filtered at 2 kHz and stored off-line for analysis with Clampfit software 478 
10.4. 479 
For two electrode voltage clamp in Xenopus laevis oocytes, human wildtype and Gly24Asp 480 
ClC-2 cRNAs were prepared from pFROG vectors (Ambion mMESSAGE mMACHINE T7 481 
kit) and injected into X. laevis oocytes, 13.8 ng and 9.2 ng per cell, respectively.  Following 482 
two days of expression at 17°C, two electrode voltage clamp was performed at room 483 
temperature using a TurboTEC amplifier (npi electronic GmbH, Tamm, Germany) and 484 
pClamp Software (Molecular Devices) to elicit ClC-2 currents (2s steps from +60mV to -485 
120mV with a final 1s step at +40mV) in ND109 solution containing (in mM): 109 NaCl, 2 486 
KCl, 1 MgCl2, 1.8 CaCl2, 2 HEPES and adjusted to pH 7.4.  To test for the typical Cl->I- 487 
selectivity of CLC channels, currents were sequentially measured in solutions containing 109 488 
mM Cl- or 109 mM I-.  To determine the pH sensitivity of currents, ND109 was buffered with 489 
5 mM MES for pH 6.5 and with 5 mM Tris for pH 8.5. Off-line analysis was performed with 490 
Clampfit software 10.4. Statistical significance was assessed using the Mann–Whitney test 491 
(Prism, GraphPad Software, USA). 492 
For patch clamp of transiently transfected H295R-S2 cells, cells were seeded at 30% 493 
confluency onto poly-L-lysine (Sigma) coated glass coverslips. Once adhered they were 494 
transfected (X-fect) with bicistronic plasmids encoding emGFP (for identification of 495 
transfected cells) and, after an an IRES sequence,  ClC-2WT or ClC-2G24D. Cells were 496 
measured 12-24 hours later. Both  transiently and stably transfected cells were measured 497 
using a Multiclamp 700B (Axon Instruments) amplifier Gramicidin-perforated patch clamp 498 
was performed to retain the intracellular chloride concentration. The tips of patch pipettes 499 
were first filled with gramicidin-free internal pipette solution (in mM): 100 KMeSO3, 30 KCl, 500 
4 NaCl, 10 Hepes, 1 MgCl2, 1 EGTA, 3 MgATP (pH 7.3, 280 mOsm/L) and then back-filled 501 
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with the same solution containing 25µg/mL gramicidin. GFP expressing cells were selected 502 
for analysis.  Approximately 20 minutes following tight giga-seal formation, stable membrane 503 
potential measurements (I=0 configuration) could be acquired with access resistances of <100 504 
MΩ in bath solution containing 140 NaCl, 5 KCl, 10 Hepes, 1.8 MgCl2, 1.8 CaCl2 (pH 7.4, 505 
300 mOsm/L). When adequate access resistance was attained (<35 MΩ), a Na+- and  K+-free 506 
bath solution containing 140 CsCl, 10 Hepes, 1.8 MgCl2, 1.8 CaCl2, 20 sucrose (pH 7.3, 300 507 
mOsm/L) was perfused to measure anion membrane currents in the voltage clamp 508 
configuration (1s steps from +60 mV to -120 mV from a holding clamp of -10 mV).  509 
Measurements were performed at room temperature (22-24°C).  Data are  presented as mean 510 
± SEM.  511 
 512 
Functional studies in H295R-S2 cells 513 
The human adrenocortical carcinoma cell line H295R strain 2 (H295R-S2), kindly 514 
provided by W. E. Rainey 41 was cultured in DMEM/Eagle’s F12 medium (GIBCO, Life 515 
technologies, Carlsbad, CA) supplemented with 2% Ultroser G (PALL life sciences, France), 516 
1% insulin/transferrin/selenium Premix (GIBCO, Life technologies, Carlsbad, CA), 10mM 517 
HEPES (GIBCO, Life technologies, Carlsbad, CA), 1% penicillin, and streptomycin (GIBCO, 518 
Life technologies, Carlsbad, CA) and maintained in a 37°C humidified atmosphere (5% 519 
CO2).   520 
For overexpression experiments, H295R-S2 cells were seeded into tissue culture dishes 100 in 521 
groups of 5.000·000 cells per dish, and maintained in the conditions described. After 24h, 522 
cells were resuspended in 100 μl Nucleofector R solution (AMAXA kit, Lonza) and 523 
transfected with 3 μg of the ClC-2WT or ClC-224Asp pFROG construct or a GFP construct, 524 
using the electroporation program P-20. To select only stably transfected cells, 48h post 525 
transfection cells were changed to medium containing 500 µg/mL G418-Genetycin (Gibco) 526 
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and used after all GFP transfected cells were dead. G418 selection was kept during all 527 
functional studies. For aldosterone measurements and RNA extraction, cells were serum 528 
deprived in DMEM/F12 containing 0.1% Ultroser G for 24h and then incubated for another 529 
24h with fresh medium containing 0.1% Ultroser G with no secretagogue or vehicle (basal), 530 
or secretagogues AngII (10nM) or  K+ (12mM), or calcium channel bloquers Nifedipine (L-531 
Type calcium channel blocker, 10µM, Sigma) or  Mibefradil (T-type calcium channel 532 
blocker, 10µM, Sigma). At the end of the incubation time, supernatant and cells from each 533 
well were harvested for aldosterone measurement and RNA extraction. Three experiments 534 
using aldosterone secretagogues (n=9) and two experiments using calcium channel blockers 535 
(n=6) were independently conducted in triplicate. 536 
Human ClC2-targeting (TRCN0000427876) and non-mammalian control (SHC002V) 537 
MISSION shRNA lentiviral transduction particles were obtained from Sigma-Aldrich. The 538 
shRNA sequences were inserted into TRC2 pLKO-puro plasmid backbone. For the lentiviral 539 
infections, manufacturer's protocol was followed with slight modifications. 1 x 104 H295R-S2 540 
cells were seeded in a 96-well plate. After 24 hours, medium was changed and supplemented 541 
with 2 μg/ml polybrene (Sigma). Lentiviral particles were then added at a multiplicity of 542 
infection of 10 and medium changed after overnight incubation. For selection, 2 μg/ml 543 
puromycin (Gibco) was added to the medium. After two passages cells were characterized in 544 
terms of mRNA expression and aldosterone production after incubation with or without 545 
secretagogue as mentioned above. 546 
 547 
RNA extraction and RT-qPCR 548 
Total RNA was extracted in Trizol reagent (Ambion Life technologies, Carlsbad CA) 549 
according to the manufacturer's recommendations. After deoxyribonuclease I treatment (Life 550 
Technologies, Carlsbad, CA), 500 ng of total RNA were retrotranscribed (iScript reverse 551 
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transcriptase, Biorad, Hercules, CA). Primers used for qPCR are described in supplementary 552 
table 3. The quantitative PCR was performed using SYBRgreen (Sso advanced universal 553 
SyBr Green supermix, Biorad, Hercules, CA) on a C1000 touch thermal cycler of Biorad 554 
(CFX96 Real Time System), according to the manufacturer's instructions. Controls without 555 
template were included to verify that fluorescence was not overestimated from primer dimer 556 
formation or PCR contaminations. RT-qPCR products were analyzed in a post amplification 557 
fusion curve to ensure that a single amplicon was obtained. Normalization for RNA quantity, 558 
and reverse transcriptase efficiency was performed against three reference genes (geometric 559 
mean of the expression of Ribosomal 18S RNA, HPRT, and GAPDH), in accordance with the 560 
MIQE guidelines 42. Quantification was performed using the standard curve method. Standard 561 
curves were generated using serial dilutions from a cDNA pool of all samples of each 562 
experiment, yielding a correlation coefficient of at least 0.98 in all experiments. 563 
 564 
Aldosterone and protein assays 565 
Aldosterone levels were measured in cell culture supernatants by ELISA. Aldosterone 566 
antibody and aldosterone-3-CMO-biotin were kindly provided by Dr Gomez-Sanchez 43. 567 
Aldosterone concentrations were normalized to cell protein concentrations (determined using 568 
Bradford protein assay). 569 
 570 
Statistical analyses 571 
Quantitative variables are reported as means ± standard error of the mean (SEM) when 572 
Gaussian distribution or medians and interquartile range when no Gaussian distribution. 573 
Pairwise comparisons were done with unpaired t-test or Mann-Whitney test respectively; 574 
multiple comparisons were done with the ANOVA test followed by a test for pairwise 575 
comparison of subgroups according to Bonferroni when Gaussian distribution, or Kruskal-576 
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Wallis followed by Dunn's test when no Gaussian distribution. Comparisons between two 577 
groups were performed with two-tailed T test or two-tailed Mann-Whitney test. A p value < 578 
0.05 was considered significant. For functional experiments, all results were expressed as 579 
mean ± SEM of three separate experiments performed in triplicate for ClC-2 overexpression 580 
studies with secretagogues, two separate experiments performed in triplicate for ClC-2 581 
expression studies with calcium channel blockers, and two to four separate experiments 582 
performed in triplicate for ClC-2 knockdown studies. Analyses were performed using Prism5 583 
(GraphPad software Inc, San Diego, CA). 584 
 585 
Data availability.  586 
The data that support the findings of this study are available from the authors on reasonable 587 
request, see author contributions for specific data sets. Disease-causing variants have been 588 
submitted to ClinVar. Exome data are available on request within a scientific cooperation. 589 
Online Methods References 590 
37. Hubert, E.L. et al. Mineralocorticoid receptor mutations and a severe recessive 591 
pseudohypoaldosteronism type 1. J. Am. Soc. Nephrol. 22, 1997-2003 (2011). 592 
38. Gunther, W., Luchow, A., Cluzeaud, F., Vandewalle, A. & Jentsch, T.J. ClC-5, the 593 
chloride channel mutated in Dent's disease, colocalizes with the proton pump in 594 
endocytotically active kidney cells. Proc. Natl. Acad. Sci. U S A 95, 8075-80 (1998). 595 
39. Gomez-Sanchez, C.E. et al. Development of monoclonal antibodies against human 596 
CYP11B1 and CYP11B2. Mol. Cell. Endocrinol. 383, 111-7 (2014). 597 
40. Hu, C., Rusin, C.G., Tan, Z., Guagliardo, N.A. & Barrett, P.Q. Zona glomerulosa cells 598 
of the mouse adrenal cortex are intrinsic electrical oscillators. J. Clin. Invest. 122, 599 
2046-53 (2012). 600 
31 
 
41. Wang, T. et al. Comparison of aldosterone production among human adrenocortical 601 
cell lines. Horm. Metab. Res. 44, 245-50 (2012). 602 
42. Bustin, S.A. et al. The MIQE guidelines: minimum information for publication of 603 
quantitative real-time PCR experiments. Clin. Chem. 55, 611-22 (2009). 604 
43. Gomez-Sanchez, C.E. et al. The production of monoclonal antibodies against 605 
aldosterone. Steroids 49, 581-7 (1987). 606 
 607 
 
 
 





